Zacks: Brainstorm Cell Therapeutics Inc. (BCLI) Given $12.00 Consensus Target Price by Analysts

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.

Brokers have set a 1 year consensus target price of $12.00 for the company and are expecting that the company will post ($0.09) EPS for the current quarter, according to Zacks. Zacks has also assigned Brainstorm Cell Therapeutics an industry rank of 98 out of 265 based on the ratings given to related companies.

Separately, Maxim Group set a $9.00 price objective on Brainstorm Cell Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, August 16th.

Hedge funds have recently modified their holdings of the business. Sphera Funds Management LTD. bought a new position in shares of Brainstorm Cell Therapeutics during the 2nd quarter valued at about $2,759,000. Vanguard Group Inc. boosted its holdings in shares of Brainstorm Cell Therapeutics by 2.8% during the 2nd quarter. Vanguard Group Inc. now owns 657,101 shares of the biotechnology company’s stock valued at $2,733,000 after purchasing an additional 17,657 shares during the last quarter. Finally, KCG Holdings Inc. boosted its holdings in shares of Brainstorm Cell Therapeutics by 4.6% during the 1st quarter. KCG Holdings Inc. now owns 41,537 shares of the biotechnology company’s stock valued at $177,000 after purchasing an additional 1,820 shares during the last quarter. Institutional investors and hedge funds own 13.08% of the company’s stock.

Shares of Brainstorm Cell Therapeutics (BCLI) remained flat at $$4.04 on Friday. The company had a trading volume of 42,214 shares, compared to its average volume of 133,354. Brainstorm Cell Therapeutics has a one year low of $2.10 and a one year high of $5.18.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last announced its earnings results on Tuesday, October 17th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. During the same quarter in the previous year, the business earned ($0.09) EPS. equities analysts anticipate that Brainstorm Cell Therapeutics will post -0.37 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This report was published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://stocknewstimes.com/2017/12/06/zacks-brainstorm-cell-therapeutics-inc-bcli-given-12-00-consensus-target-price-by-analysts.html.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.

Get a free copy of the Zacks research report on Brainstorm Cell Therapeutics (BCLI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Brainstorm Cell Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply